1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2020, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape.
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Non-Hodgkin Lymphoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 29, 2, 36, 204, 206, 8, 25, 192, 21 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 28, 34, 3, 37, 6 and 1 molecules, respectively.
Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionNon-Hodgkin Lymphoma - Overview
Non-Hodgkin Lymphoma - Therapeutics Development
Non-Hodgkin Lymphoma - Therapeutics Assessment
Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
Non-Hodgkin Lymphoma - Drug Profiles
Non-Hodgkin Lymphoma - Dormant Projects
Non-Hodgkin Lymphoma - Discontinued Products
Non-Hodgkin Lymphoma - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Non-Hodgkin Lymphoma, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by 4SC AG, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by ABIONYX Pharma SA, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Abologix Sarl, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by ACEA Therapeutics Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Acerta Pharma BV, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Acrotech Biopharma LLC, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Adagene Suzhou Ltd, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics SA, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Adicet Bio Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Adienne Pharma & Biotech, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Advenchen Laboratories LLC, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by AGC Biologics SpA, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by AgenTus Therapeutics Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Agenus Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Agios Pharmaceuticals Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by AI Therapeutics Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Akeso Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Aleta Biotherapeutics Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Alfasigma SpA, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Allarity Therapeutics A/S, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Alopexx Oncology LLC, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Alphamab Oncology, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by ALX Oncology Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Anew Oncology Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Angiocrine Bioscience Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Antengene Corp, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by AP Biosciences Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Apollomics Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Apotex Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Applied Therapeutics Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Aprea Therapeutics Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Archigen Biotech Ltd, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Argenx SE, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals LLC, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Ascentage Pharma Group International, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by AUM Biosciences Pte Ltd, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Autolus Therapeutics Plc, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Avalon GloboCare Corp, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Avipep Pty Ltd, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by AVM Biotechnology LLC, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Lupin Ltd, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H2 2020
- Non-Hodgkin Lymphoma - Pipeline by Mablink Bioscience, H2 2020
List of Figures
- Number of Products under Development for Non-Hodgkin Lymphoma, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- 4SC AG
- A. Menarini Industrie Farmaceutiche Riunite Srl
- AB Science SA
- AbbVie Inc
- ABIONYX Pharma SA
- Abologix Sarl
- ACEA Therapeutics Inc
- Acerta Pharma BV
- Acrotech Biopharma LLC
- Actinium Pharmaceuticals Inc
- Adagene Suzhou Ltd
- ADC Therapeutics SA
- Adicet Bio Inc
- Adienne Pharma & Biotech
- Adlai Nortye Biopharma Co Ltd
- Advenchen Laboratories LLC
- Affimed GmbH
- Affitech A/S
- AGC Biologics SpA
- AgenTus Therapeutics Inc
- Agenus Inc
- Agios Pharmaceuticals Inc
- AI Therapeutics Inc
- Akeso Inc
- Aleta Biotherapeutics Inc
- Alexion Pharmaceuticals Inc
- Alfasigma SpA
- Allarity Therapeutics A/S
- Alopexx Oncology LLC
- Alphamab Oncology
- ALX Oncology Inc
- Amgen Inc
- Anew Oncology Inc
- Angimmune LLC
- Angiocrine Bioscience Inc
- Anhui Anke Biotechnology (Group) Co Ltd
- Antengene Corp
- AP Biosciences Inc
- Apollomics Inc
- Apotex Inc
- Applied Therapeutics Inc
- Aprea Therapeutics Inc
- Archigen Biotech Ltd
- Argenx SE
- Arrien Pharmaceuticals LLC
- Ascentage Pharma Group International
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- AUM Biosciences Pte Ltd
- Aurigene Discovery Technologies Ltd
- Autolus Therapeutics Plc
- Avalon GloboCare Corp
- Avipep Pty Ltd
- AVM Biotechnology LLC
- AzarGen Biotechnologies (Pty) Ltd
- Bantam Pharmaceutical LLC
- Bayer AG
- BeiGene Ltd
- Beijing GD Initiative Cell Therapy Technology Co Ltd
- Beijing Immunochina Pharmaceuticals Co Ltd
- Beijing Luzhu Biotechnology Co Ltd
- Beijing Mabworks Biotech Co Ltd
- Beijing Shenzhou Cell Biotechnology Group Co Ltd
- Bellicum Pharmaceuticals Inc
- BendaRx Corp
- Betta Pharmaceuticals Co Ltd
- Bio-Path Holdings Inc
- Bio-Thera Solutions Ltd
- BioCurate Pty Ltd
- BioEclipse Therapeutics Inc
- Biogen Inc
- BioIntegrator Ltd
- BioInvent International AB
- BioLineRx Ltd
- Bioniz Therapeutics Inc
- BioNTech SE
- BioPact Ventures LLC
- BioXpress Therapeutics SA
- BiVictriX Therapeutics Ltd
- bluebird bio Inc
- Boehringer Ingelheim International GmbH
- Boryung Pharmaceutical Co Ltd
- Boryung ViGenCell Inc
- Brickell Biotech Inc
- Bristol-Myers Squibb Co
- C4 Therapeutics Inc
- Cardiff Oncology Inc
- Caribou Biosciences Inc
- Carrick Therapeutics Ltd
- CARsgen Therapeutics Ltd
- Cartherics Pty Ltd
- CASI Pharmaceuticals Inc
- Catalent Inc
- Catapult Therapeutics BV
- Celdara Medical LLC
- Cell Source Inc
- Cell>Point LLC
- CellCentric Ltd
- Celldex Therapeutics Inc
- Cellectar Biosciences Inc
- Cellectis SA
- Celleron Therapeutics Ltd
- Cellestia Biotech AG
- Celltrion Inc
- Cellular Biomedicine Group Inc
- Cellular Biomedicine Group Ltd
- Celularity Inc
- Centrose LLC
- CerRx Inc
- CGeneTech (Suzhou China) Co Ltd
- Checkmate Pharmaceuticals Inc
- Checkpoint Therapeutics Inc
- Chengdu Brilliant Pharmaceutical Co Ltd
- China Immunotech Co Ltd
- CHO Pharma Inc
- Chordia Therapeutics Inc
- Chugai Pharmaceutical Co Ltd
- Cielo Therapeutics Inc
- Clayton Biotechnologies Inc
- Clevexel Pharma SA
- Codiak BioSciences Inc
- Cogent Biosciences Inc
- CoImmune Inc
- Constellation Pharmaceuticals Inc
- Corvus Pharmaceuticals Inc
- CRISPR Therapeutics AG
- CrystalGenomics Inc
- CSL Ltd
- CSPC Pharmaceutical Group Ltd
- CStone Pharmaceuticals Co Ltd
- Cullinan Oncology LLC
- Curis Inc
- Curocell Inc
- Cyclacel Pharmaceuticals Inc
- Cyteir Therapeutics Inc
- CytomX Therapeutics Inc
- Daiichi Sankyo Co Ltd
- Daysai Biopharmaceuticals Inc
- Debiopharm International SA
- Decoy Biosystems Inc
- Denovo Biopharma LLC
- Dizal (Jiangsu) Pharmaceutical Co Ltd
- Dr. Reddy's Laboratories Ltd
- Dragonfly Therapeutics Inc
- eFFECTOR Therapeutics Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Enterome Bioscience SA
- Epidestiny Inc
- Epizyme Inc
- ERYTECH Pharma SA
- Esanex Inc
- Eternity Bioscience Inc
- Eureka Therapeutics Inc
- Eutilex Co Ltd
- Evive Biotech
- Evotec SE
- Exinda Therapeutics LLC
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Fujifilm Holdings Corp
- Galderma SA
- Gamida Cell Ltd
- GC Pharma
- Geneius Biotechnology Inc
- Genentech USA Inc
- Geneos Therapeutics Inc
- GeneScience Pharmaceuticals Co Ltd
- Genexine Inc
- GenFleet Therapeutics (Shanghai) Inc
- Genmab AS
- Genor BioPharma Co Ltd
- Genosco Inc
- Gibson Oncology LLC
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- GPCR Therapeutics Inc
- Gracell Biotechnology Ltd
- Grupo Ferrer Internacional SA
- GT Biopharma Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Guangzhou Bio-gene Technology Co Ltd
- H3 Biomedicine Inc
- Hangzhou Hezheng Pharmaceutical Co Ltd
- Hangzhou Minsheng Pharmaceutical Group Co Ltd
- Hangzhou Zenshine Pharmaceuticals Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- Harpoon Therapeutics Inc
- Hebei Senlang Biotechnology Inc Ltd
- HEC Pharm Co Ltd
- Heidelberg Pharma AG
- Helocyte Biosciences Inc
- Helsinn Group
- Hengenix Biotech Inc
- Hibercell Inc
- HRAIN Biotechnology Co Ltd
- Hualan Biological Engineering Inc
- Humanigen Inc
- Hunan Siweikang Therapeutics Ltd
- Hutchison MediPharma Ltd
- I-Mab
- iBio Inc
- iCell Gene Therapeutics LLC
- IGM Biosciences Inc
- Iksuda Therapeutics Ltd
- ImCheck Therapeutics SAS
- Immune Cell Inc
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- ImmuneTarget Inc
- ImmunityBio Inc
- ImmunoGen Inc
- Immunomet Therapeutics Inc
- Immunotech Biopharm Ltd
- Impetis Biosciences Ltd
- IMV Inc
- Inatherys
- Incuron LLC
- Incyte Corp
- Inflection Biosciences Ltd
- Inhibrx Inc
- Innate Pharma SA
- InnoCare Pharma Ltd
- Innovative Cellular Therapeutics Co Ltd
- Innovent Biologics Inc
- IO Biotech ApS
- Ionis Pharmaceuticals Inc
- Japan Tobacco Inc
- Jazz Pharmaceuticals Plc
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Maidu Drug Research and Development Co Ltd
- JN Biosciences LLC
- Johnson & Johnson
- Jubilant Therapeutics Inc
- Juno Therapeutics Inc
- Juventas Cell Therapy Ltd
- JW Therapeutics Shanghai Co Ltd
- Kainos Medicine Inc
- Kangpu Biopharmaceuticals Ltd
- Kartos Therapeutics Inc
- Karus Therapeutics Ltd
- Karyopharm Therapeutics Inc
- Kecellitics Biotech Co Ltd
- Kiniksa Pharmaceuticals Ltd
- Kiromic BioPharma Inc
- Klyss Biotech Inc
- Komipharm International Co Ltd
- Kronos Bio Inc
- Kuur Therapeutics Ltd
- Kymera Therapeutics LLC
- Kyowa Kirin Co Ltd
- Lanzhou Institute of Biological Products Co Ltd
- Legend Biotech Corp
- LegoChem Biosciences Inc
- Lepu Medical Technology (Beijing) Co Ltd
- Les Laboratoires Servier SAS
- LFB SA
- Light Chain Bioscience
- LintonPharm Co Ltd
- Loxo Oncology Inc
- Luminary Therapeutics Inc
- Lupin Ltd
- Mabion SA
- Mablink Bioscience
- Machavert Pharmaceuticals LLC
- MacroGenics Inc
- Magenta Therapeutics Inc
- ManysmarT Therapeutics Inc
- Marino Biotechnology Co Ltd
- Marker Therapeutics Inc
- Meabco AS
- MedC Biopharma Ltd
- MediGene AG
- MediSix Therapeutics Pte Ltd
- Meditope Biosciences Inc
- Medivir AB
- MedPacto Inc
- MEI Pharma Inc
- MENTRIK Biotech LLC
- Merck & Co Inc
- Merck KGaA
- Millennium Pharmaceuticals Inc
- Miltenyi Biotec BV & Co KG
- Miragen Therapeutics Inc
- Mirati Therapeutics Inc
- Moderna Inc
- Molecular Templates Inc
- Moleculin Biotech Inc
- MorphoSys AG
- Mustang Bio Inc
- Myeloid Therapeutics Inc
- Nanjing Bioheng Biotech Co Ltd
- Nanjing Iaso Biotherapeutics Co Ltd
- Nanjing KAEDI Biotech Inc
- Nanjing Sanhome Pharmaceutical Co Ltd
- Nanolek LLC
- Nanoligent SL
- NantKwest Inc
- Navrogen Inc
- Nektar Therapeutics
- Neoleukin Therapeutics Inc
- Neonc Technologies Inc
- Neumedicines Inc
- Newave Pharmaceutical Inc
- NewBio Therapeutics Inc
- Nichi-Iko Pharmaceutical Co Ltd
- Nordic Nanovector ASA
- Northlake International LLC
- NovalGen Ltd
- Novartis AG
- Onco Therapies Inc
- Oncoceutics Inc
- Onconova Therapeutics Inc
- Oncopeptides AB
- OncoTartis Inc
- Oncovir Inc
- Oncternal Therapeutics
- OnKure Inc
- Ono Pharmaceutical Co Ltd
- Orano Med LLC
- Orsenix Holdings BV
- Otsuka Holdings Co Ltd
- Oxford BioTherapeutics Ltd
- Pacylex Pharmaceuticals Inc
- PeproMene Bio Inc
- PersonGen Biomedicine Suzhou Co Ltd
- PersonGen BioTherapeutics Suzhou Co Ltd
- Pfizer Inc
- Pharmapraxis
- Philogen SpA
- PIQUR Therapeutics AG
- Plexxikon Inc
- Precision Biosciences Inc
- Prelude Therapeutics Inc
- Prescient Therapeutics Ltd
- Protheragen Inc
- Quimatryx SL
- Rafael Pharmaceuticals Inc
- RAPT Therapeutics Inc
- Regeneron Pharmaceuticals Inc
- Replimune Ltd
- Rescue Therapeutics Inc
- Respiratorius AB
- Rhizen Pharmaceuticals SA
- Ribon Therapeutics Inc
- Ryvu Therapeutics SA
- Samumed LLC
- Sanofi
- Sareum Holdings Plc
- SciTech Development LLC
- Scopus BioPharma Inc
- Seagen Inc
- Secura Bio Inc
- selectION Inc
- Senhwa Biosciences Inc
- SHAL Technologies Inc
- Shandong New Time Pharmaceutical Co Ltd
- Shandong Qidu Pharmaceutical Co Ltd
- Shanghai Bioray Laboratory Inc
- Shanghai Cell Therapy Group Co
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Shanghai GeneChem Co Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shanghai Institute of Biological Products Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Longyao Biotechnology Inc Ltd
- Shanghai Miracogen Inc
- Shanghai Pharmaceutical Group Co Ltd
- Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
- Shanghai YaKe Biotechnology Inc
- Shanghai Yingli Pharmaceutical Co Ltd
- Shattuck Labs Inc
- Shengke Pharmaceuticals (Jiangsu) Ltd
- Shenzhen BinDeBio Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Sian Wuhan Medical Technology Co Ltd
- Sichuan Haisco Pharmaceutical Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- SideROS
- SignalRx Pharmaceuticals Inc
- Sino Biopharmaceutical Ltd
- SinoMab Bioscience Ltd
- Solasia Pharma KK
- Soligenix Inc
- Sonoval LLC
- Sorrento Therapeutics Inc
- SpecificiT Pharma Inc
- Spectrum Pharmaceuticals Inc
- SumiQ Therapeutics BV
- Sumitomo Dainippon Pharma Oncology, Inc
- Supratek Pharma Inc
- Surface Oncology Inc
- Sutro Biopharma Inc
- Suzhou Sinovent Pharmaceuticals Co Ltd
- Syndax Pharmaceuticals Inc
- Systimmune Inc
- Tacitus Therapeutics Inc
- Taiwan Liposome Co Ltd
- Takara Bio Inc
- Takeda Pharmaceutical Co Ltd
- Tayu Huaxia Biotech Medical Group Co Ltd
- TC BioPharm Ltd
- TCR Cure Biopharma Technology Co Ltd
- TCR2 Therapeutics Inc
- TeneoBio Inc
- Tessa Therapeutics Ltd
- TG Therapeutics Inc
- Timmune Biotech Inc
- TOT Biopharm Co Ltd
- Transgene Biotek Ltd
- Transgene SA
- Trillium Therapeutics Inc
- Triphase Accelerator Corp
- Triumvira Immunologics Inc
- Truvitech LLC
- Turning Point Therapeutics Inc
- Tyme Technologies Inc
- United BioPharma Inc
- UWELL Biopharma Inc
- VelosBio Inc
- Vidac Pharma Ltd
- Vincera Pharma Inc
- Viracta Therapeutics Inc
- Vivolux AB
- VM Discovery Inc
- Vyriad Inc
- Wellington Zhaotai Therapies Ltd
- Wugen Inc
- Wuhan Bio-Raid Biotechnology Co Ltd
- X4 Pharmaceuticals Inc
- Xcovery Holding Co LLC
- XEME BioPharma Inc
- Xencor Inc
- Xenetic Biosciences Inc
- Xynomic Pharmaceuticals Holdings Inc
- Xyphos Biosciences Inc
- Zentalis Pharmaceuticals Inc
- Zhejiang DTRM Biopharma LLC
- Zhejiang Hisun Pharmaceutical Co Ltd
- Zhejiang Teruisi Pharmaceutical Co Ltd
- Zhengda Tianqing Pharmaceutical Group Co Ltd
- Zhuobo Yong Ji (Shanghai) Biological Pharmaceutical Co Ltd
- ZIOPHARM Oncology Inc
- Zumutor Biologics Inc
- Zymeworks Inc
